Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)

This study is ongoing, but not recruiting participants.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Oxford Identifier:
First received: November 24, 2010
Last updated: May 29, 2015
Last verified: May 2015